Biogen Pre-Announces Significant Q2 & Q3 R&D Charges, Impacting EPS by up to $2.90/Share
BIIB sits 73% above its 52-week low of $121.05.
Summary
Biogen expects to incur significant R&D and milestone expenses in Q2 and Q3 2026, leading to an estimated combined EPS reduction of up to $2.90 per share.
Key Events · Earnings and Guidance · BIIB
-
Q2 2026 EPS Impact
Biogen anticipates approximately $164 million in pre-tax acquired in-process R&D, upfront, and milestone expenses for Q2 2026, impacting EPS by about $0.95 per share.
-
Q3 2026 EPS Impact
The company expects Q3 2026 to include $290 million to $320 million in similar expenses, leading to an estimated EPS reduction of $1.75 to $1.95 per share.
-
Preliminary Estimates
These figures are preliminary and unaudited, subject to final financial statement closing procedures.
Analysis · BIIB · Life Sciences
Biogen is pre-announcing substantial acquired in-process R&D, upfront, and milestone expenses for Q2 and Q3 2026. These charges, totaling approximately $454 million to $484 million, will significantly reduce reported GAAP and non-GAAP earnings per share for both quarters. This update indicates higher-than-anticipated costs related to collaborations and acquisitions, which could lead to further downward revisions of full-year profit forecasts and negatively impact investor sentiment, especially as the stock trades near its 52-week high.
At the time of this filing, BIIB was trading at $209.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31B. The 52-week trading range was $121.05 to $219.72. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.